CAY 001
Alternative Names: CAY-001Latest Information Update: 29 Aug 2024
At a glance
- Originator Cayuga Biotech
- Class Anticoagulants; Antihaemorrhagics; Polyphosphates
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Blood coagulation disorders; Haemorrhage
- Research Wounds